Insilico and SK Biopharmaceuticals Ink $2.5 Billion AI Drug Deal
Insilico Medicine and SK Biopharmaceuticals have launched a major research partnership targeting neuroimmune disorders, a deal valued at up to $2.5 billion. Announced at the BIO 2026 International Convention, the collaboration combines Insilico’s generative AI platform with the clinical commercialization expertise of the Korean biotech leader.

























